Telix Pharmaceuticals prices A$650m 2.375% convertible notes due 2029 for low-cost financing.
Telix Pharmaceuticals Limited successfully priced A$650m 2.375% convertible notes due 2029, with strong global support from eligible investors. The convertible notes, also known as "convertible bonds", are convertible into fully paid ordinary shares in Telix. The initial conversion price is A$24.78 per ordinary share, offering attractive, low-cost financing to Telix.
July 23, 2024
8 Articles